Американское общество гирудотерапии

Breast Reconstruction Flap Salvage

FDA-cleared application: venous decompression of compromised DIEP, TRAM, and latissimus dorsi flaps in post-mastectomy reconstruction.

Tier A — FDA-cleared indicationFDA-допуск медицинского изделияLast updated: 2026-05-26 · Reviewed by ASH Editorial Board

Краткая информация для пациента

Есть ли FDA-допуск для этого показания?
Yes — FDA-cleared under K040187 (June 21, 2004) for medicinal leech application to relieve venous congestion in microsurgical reconstructive procedures, including breast reconstruction flaps.
Какие доказательства существуют?
This is an FDA-cleared use. The largest published hospital series (Nguyen 2012, n=154) reports that about 78 percent of congested DIEP flaps were saved when leech therapy was added to surgical re-exploration. Major U.S. cancer centers (MD Anderson, Memorial Sloan Kettering, Mayo) include leech availability in their post-operative protocols. Leeches do not replace surgery — if the issue is an artery problem or a fixable surgical clot, the surgical team must address that first.
Основные риски
  • Bleeding from each bite site for 6 to 10 hours after the leech detaches
  • Need for blood transfusion (about 1 in 3 patients) from cumulative blood loss over the treatment course
  • Aeromonas hydrophila infection (your team starts an antibiotic such as ciprofloxacin before the first leech)
  • Loss of the flap despite treatment if the underlying artery problem cannot be fixed
  • Allergic reaction to leech saliva (uncommon)
  • Visible bite-mark scarring on the reconstructed breast that may fade but may not disappear entirely
  • Longer hospital stay and emotional stress from a complication after an already long surgery
Кому не следует это рассматривать
  • Patients on warfarin, apixaban, rivaroxaban, dabigatran, or heparin
  • Patients with hemophilia or another inherited bleeding disorder
  • Patients with severe anemia (hemoglobin under 10 g/dL) before therapy
  • Patients with active bloodstream infection or sepsis
  • Patients allergic to ciprofloxacin and other antibiotics covering Aeromonas
  • Patients whose flap has completely died (no salvage is possible — surgical removal is needed)
  • Patients whose flap problem is an artery issue (this requires surgical revision, not leeches)
О чём спросить врача
  • Is this an artery problem, a vein problem, or both? Leeches only help with vein problems.
  • Should I be taken back to the operating room before or instead of starting leech therapy?
  • Which antibiotic will I get for Aeromonas prevention, and for how long?
  • How often will my blood count be checked, and at what level would you transfuse?
  • How will the bite scars look once everything heals, and is there anything that helps them fade?
  • If the flap fails despite leeches, what are my options — a new flap from a different site, an implant, or no reconstruction?
  • Will my breast cancer follow-up care be affected by this complication or by the transfusions?
Когда срочно обратиться за медицинской помощью
  • Bleeding from any bite site soaking through more than one dressing per hour, or bleeding lasting more than 24 hours after the leech detaches
  • Increasing redness, warmth, swelling, or pus around the flap or bite sites
  • Fever above 38.0 C / 100.4 F, chills, or feeling suddenly unwell
  • Flap turning darker, colder, or harder despite leech therapy
  • Hives, swelling of the face or tongue, or any breathing difficulty

Что это НЕ означает

  • It does not mean the flap is guaranteed to survive — about 20 to 40 percent of severely congested flaps are still lost, especially when the artery is the real problem.
  • It does not mean leeches replace surgical re-exploration — for early problems (less than 6 hours after surgery) the team will usually take you back to the operating room first.
  • It does not mean home use is safe — this is hospital therapy with antibiotics and blood-count monitoring.
  • It does not affect your cancer outcome — leech therapy is for the reconstruction, not the cancer treatment.

Clinical Profile

Category
surgical reconstruction
ICD-10
T86.821, T87.41, N64.89, Z90.13
Safety tier
high

Evidence Summary

Free flap breast reconstruction (DIEP, TRAM, SIEA, PAP, latissimus) has a venous compromise rate of 3-7%. Early identification (within hours) and prompt leech application can support flap salvage in a substantial fraction of cases that would otherwise progress toward total flap loss. Evidence is drawn from mixed-flap experience rather than breast-specific trials: a 2012 systematic review of 277 reported clinical cases of leech therapy across plastic and reconstructive surgery found an overall success (salvage) rate of about 78%, while a 2012 retrospective series of 39 patients with venous congestion found that among 27 regional and free flaps roughly one-third were fully salvaged, one-third partially salvaged, and one-third lost. Routine institutional protocols at major reconstructive centers include leech availability in the postoperative pathway. Leech therapy does not replace surgical re-exploration for arterial issues or for early venous compromise where revision of the anastomosis is feasible.

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)

Key Trials

  1. Nguyen MQ et al. (2012), n=39 · PMID 22473683 · ASH analysis →
  2. Knobloch K et al. (2007)0 · PMID 17497605 · ASH analysis →
  3. Whitaker IS et al. (2012), n=277 · PMID 22407551 · ASH analysis →
Sample sizes of key trials for Breast Reconstruction Flap SalvageNguyen MQ et al. 201239Whitaker IS et al. 2012277
Participants per key trial (n). Larger trials generally carry more statistical weight; case series with unspecified counts are omitted.
Study-design composition of the evidence base for Breast Reconstruction Flap Salvage3studies
  • Cohort: 1 (33%)
  • Systematic Review: 2 (67%)
Composition of the cited evidence base by study design, from strongest (meta-analysis, systematic review) to weakest (case report). A base weighted toward RCTs and reviews is more reliable.

Contraindications

  • Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
  • Hemophilia or other bleeding disorder
  • Severe anemia (Hb <10 g/dL)
  • Active bacteremia or sepsis
  • Known hypersensitivity to leech salivary proteins
  • Pregnancy (relative — first/third trimester)
  • Immunocompromised state with severe neutropenia
  • Total flap necrosis (non-salvageable; proceed to debridement)
  • Arterial insufficiency (must address surgically before leeching)

Related Conditions

Этот сайт предоставляет образовательную информацию и не является медицинской консультацией, диагнозом или рекомендацией по лечению. Гирудотерапия сопряжена с клинически значимыми рисками и должна проводиться только квалифицированными клиницистами в рамках институционально утверждённых протоколов. Разрешение FDA 510(k) для медицинских пиявок ограничено определёнными показаниями; обсуждения исследовательского и нелицензионного применения отмечены соответствующим образом. Для индивидуальных медицинских рекомендаций обратитесь к квалифицированному медицинскому специалисту.

Breast Reconstruction Flap Salvage — Hirudotherapy Evidence | ASH